Narayan on Complete Responses, Biomarkers, and Side Effects of Nadofaragene Treatment for NMIBC

Video

Vikram Narayan, MD, expanded on his data regarding nadofaragene and NMIBC published at this year’s SUO Meeting.

Vikram Narayan, MD, touched on the findings from research published at the 21st Annual Meeting of the Society of Urologic Oncology in an interview with CancerNetwork. He spoke about complete responses, biomarkers and the side effect profile of nadofaragene to treat patients with non-muscle invasive bladder cancer (NMIBC).

Transcription:

I think in terms of what these studies show us is that it first shows us that nadofaragene when used in patients with BCGN-responsive disease does provide for a complete response rate in about half of patients. In those who achieve a complete response, its reasonably durable out to a year and there are very few recurrences thereafter. We’ve also potentially identified a biomarker that we can use to assess for treatment responses and potentially incorporate them into future studies.

Additionally, the other big finding is that the agent has a very favorable side effect profile with most patients primarily experiencing only temporary discomfort mostly related to urinary symptoms when the medication is administered. Only 4 patients in the entire study discontinued the drug due to side effects. This is significant because compared with pembrolizumab, which was the other agent which was an agent approved by the FDA earlier this year for the same indication, nadofaragene appears to have much less risk of toxicity and more importantly, it’s not a systemic agent meaning it’s not given intravenously. So, it may be of preference to patients who are trying to avoid some of those side effects.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content